BCS Class 3 Biowaivers and Transporter Considerations

Presentation - James E. Polli University of Maryland

  • Background
  • Prior human in vivo studies
  • Recent series of in vivo human studies of 14 common excipients
  • Potential transporter (or enzyme or nuclear receptor) x excipient interaction concern
  • Conclusions
Download
BCS Class 3 Biowaivers and Transporter Considerations
James E. Polli
jpolli@rx.umaryland.edu
October 27, 2015
355.pdf
Adobe Acrobat Document 1.7 MB